XML 25 R13.htm IDEA: XBRL DOCUMENT
v3.23.1

Balance Sheet Components | 3 Months Ended
--- | ---
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Components | 5. Balance Sheet Components Cash and Cash Equivalents Cash and cash equivalents consisted of the following (in thousands):
|  | March 31, 2023 |  |  | December 31, 2022 |
Cash |  | $ | 145,810 |  |  | $ | 135,819 |
Money market funds |  |  | 42,740 |  |  |  | 19,881 |
Total cash and cash equivalents |  | $ | 188,550 |  |  | $ | 155,700 |
At March 31, 2023 and December 31, 2022, a total of $98.9 million and $92.5 million of the Company’s cash and cash equivalents were held outside of the U.S. in its foreign subsidiaries to be used primarily for its China operations, respectively. Investments The Company’s investments consist primarily of available-for-sale debt investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major investments type are summarized in the tables below (in thousands):
|  | March 31, 2023 |
|  | Amortized Cost |  |  | Gross Unrealized Holding Gains |  |  | Gross Unrealized Holding Losses |  |  | Estimated Fair Value |
Corporate bonds |  | $ | 41,760 |  |  | $ | 1 |  |  | $ | (457 | ) |  | $ | 41,304 |
Commercial paper |  |  | 42,970 |  |  |  | — |  |  |  | — |  |  |  | 42,970 |
U.S. government bonds |  |  | 72,130 |  |  |  | 1 |  |  |  | (565 | ) |  |  | 71,566 |
Agency bonds |  |  | 9,183 |  |  |  | — |  |  |  | (108 | ) |  |  | 9,075 |
Asset-backed securities |  |  | 2,491 |  |  |  | — |  |  |  | (7 | ) |  |  | 2,484 |
Total investments |  | $ | 168,534 |  |  | $ | 2 |  |  | $ | (1,137 | ) |  | $ | 167,399 |
|  | December 31, 2022 |
|  | Amortized Cost |  |  | Gross Unrealized Holding Gains |  |  | Gross Unrealized Holding Losses |  |  | Estimated Fair Value |
Corporate bonds |  | $ | 83,080 |  |  | $ | — |  |  | $ | (1,072 | ) |  | $ | 82,008 |
Commercial paper |  |  | 57,381 |  |  |  | — |  |  |  | — |  |  |  | 57,381 |
U.S. government bonds |  |  | 112,547 |  |  |  | 5 |  |  |  | (1,207 | ) |  |  | 111,345 |
Agency bonds |  |  | 11,690 |  |  |  | — |  |  |  | (222 | ) |  |  | 11,468 |
Asset-backed securities |  |  | 2,484 |  |  |  | — |  |  |  | (10 | ) |  |  | 2,474 |
Foreign government bonds |  |  | 5,007 |  |  |  | — |  |  |  | (27 | ) |  |  | 4,980 |
Convertible promissory note |  |  | 1,000 |  |  |  | — |  |  |  | — |  |  |  | 1,000 |
Total investments |  | $ | 273,189 |  |  | $ | 5 |  |  | $ | (2,538 | ) |  | $ | 270,656 |
The following table summarizes, for all available for sale securities in an unrealized loss position, the fair value and gross unrealized loss by length of time the security has been in a continual unrealized loss position (in thousands):
|  | March 31, 2023 |
|  | Less than 12 Months |  |  | 12 Months or More |  |  | Total |
|  | Estimated Fair Value |  |  | Gross Unrealized Holding Losses |  |  | Estimated Fair Value |  |  | Gross Unrealized Holding Losses |  |  | Estimated Fair Value |  |  | Gross Unrealized Holding Losses |
Corporate bonds |  | $ | 2,469 |  |  | $ | (7 | ) |  | $ | 36,084 |  |  | $ | (450 | ) |  | $ | 38,553 |  |  | $ | (457 | )
U.S. government bonds |  |  | 4,955 |  |  |  | (1 | ) |  |  | 43,794 |  |  |  | (564 | ) |  |  | 48,749 |  |  |  | (565 | )
Agency bonds |  |  | — |  |  |  | — |  |  |  | 9,075 |  |  |  | (108 | ) |  |  | 9,075 |  |  |  | (108 | )
Asset-backed securities |  |  | 2,483 |  |  |  | (7 | ) |  |  | — |  |  |  | — |  |  |  | 2,483 |  |  |  | (7 | )
Total |  | $ | 9,907 |  |  | $ | (15 | ) |  | $ | 88,953 |  |  | $ | (1,122 | ) |  | $ | 98,860 |  |  | $ | (1,137 | )
|  | December 31, 2022 |
|  | Less than 12 Months |  |  | 12 Months or More |  |  | Total |
|  | Estimated Fair Value |  |  | Gross Unrealized Holding Losses |  |  | Estimated Fair Value |  |  | Gross Unrealized Holding Losses |  |  | Estimated Fair Value |  |  | Gross Unrealized Holding Losses |
Corporate bonds |  | $ | 6,738 |  |  | $ | (147 | ) |  | $ | 75,270 |  |  | $ | (925 | ) |  | $ | 82,008 |  |  | $ | (1,072 | )
U.S. government bonds |  |  | 22,326 |  |  |  | (13 | ) |  |  | 67,909 |  |  |  | (1,194 | ) |  |  | 90,235 |  |  |  | (1,207 | )
Agency bonds |  |  | — |  |  |  | — |  |  |  | 11,468 |  |  |  | (222 | ) |  |  | 11,468 |  |  |  | (222 | )
Asset-backed securities |  |  | 2,474 |  |  |  | (10 | ) |  |  | — |  |  |  | — |  |  |  | 2,474 |  |  |  | (10 | )
Foreign government bonds |  |  | - |  |  |  | — |  |  |  | 4,980 |  |  |  | (27 | ) |  |  | 4,980 |  |  |  | (27 | )
Total |  | $ | 31,538 |  |  | $ | (170 | ) |  | $ | 159,627 |  |  | $ | (2,368 | ) |  | $ | 191,165 |  |  | $ | (2,538 | )
At March 31, 2023, the available-for-sale investments had remaining contractual maturities of less than twelve months. The Company periodically reviews its available-for-sale investments for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. Based on the results of its review, the Company did no t recognize any other-than-temporary impairment loss during the three months ended March 31, 2023 and 2022. Inventories Inventories consisted of the following (in thousands):
|  | March 31, 2023 |  |  | December 31, 2022 |
Raw materials |  | $ | 1,226 |  |  | $ | 1,241 |
Work-in-progress |  | $ | 37,273 |  |  |  | 36,003 |
Finished goods |  | $ | 3,957 |  |  |  | 3,192 |
Total inventories |  | $ | 42,456 |  |  | $ | 40,436 |
Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands):
|  | March 31, 2023 |  |  | December 31, 2022 |
Preclinical and clinical trial accruals |  | $ | 42,953 |  |  | $ | 57,780 |
API and bulk drug product price true-up |  |  | 30,758 |  |  |  | 75,055 |
Payroll and related accruals |  |  | 12,230 |  |  |  | 22,562 |
Accrued co-promotion expenses - current |  |  | 36,688 |  |  |  | 36,677 |
Roxadustat profit share to AstraZeneca |  |  | 7,311 |  |  |  | 7,280 |
Property taxes and other taxes |  |  | 8,041 |  |  |  | 7,691 |
Professional services |  |  | 8,354 |  |  |  | 5,480 |
Current portion of liability related to sale of future revenues |  |  | 3,212 |  |  |  | — |
Other |  |  | 7,495 |  |  |  | 7,248 |
Total accrued and other current liabilities |  | $ | 157,042 |  |  | $ | 219,773 |
The accrued liabilities of $30.8 million for API and bulk drug product price true-up as of March 31, 2023 resulted from changes in estimated variable consideration associated with the API shipments fulfilled under the terms of the Astellas Japan Amendment, the bulk drug product transferred under the terms of the Astellas Europe Agreement and the Astellas EU Supply Agreement, and the bulk drug product shipments to AstraZeneca under the terms of the AstraZeneca Master Supply Agreement. See the Drug Product Revenue section in Note 2, Collaboration Agreements, License Agreement and Revenues, for details.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration